特应性皮炎治疗的新趋势与新兴趋势
New and emerging trends in the treatment of atopic dermatitis.
作者信息
Gelbard Christina M, Hebert Adelaide A
机构信息
Departments of Dermatology;
出版信息
Patient Prefer Adherence. 2008 Feb 2;2:387-92.
Atopic dermatitis is a chronic, inflammatory skin condition that affects 10% to 20% of children and 1% to 3% of adults in the US. Symptoms often result in sleeplessness, psychological stress, poor self-esteem, anxiety, and poor school or work performance. The cost of atopic dermatitis is estimated to be US$0.9 to 3.8 billion every year. Topical steroids are first-line treatment for atopic dermatitis, and recent advances in vehicle technologies have resulted in improved patient tolerability and compliance. Topical calcineurin inhibitors are also safe and effective topical treatments for atopic dermatitis, and provide an additional therapeutic option for patients with this disease. Systemic immunomodulators are used in the treatment of severe refractory disease. Cyclosporine, methotrexate, azathioprine, mycophenolate mofetil, and interferon gamma have been used in the management of severe atopic dermatitis. This review highlights the current and emerging trends in the treatment of atopic dermatitis.
特应性皮炎是一种慢性炎症性皮肤病，在美国影响10%至20%的儿童和1%至3%的成年人。症状常常导致失眠、心理压力、自卑、焦虑以及学习或工作表现不佳。据估计，特应性皮炎每年的花费为9亿至38亿美元。外用糖皮质激素是特应性皮炎的一线治疗方法，载体技术的最新进展已提高了患者的耐受性和依从性。外用钙调神经磷酸酶抑制剂也是治疗特应性皮炎安全有效的外用疗法，为患有这种疾病的患者提供了额外的治疗选择。全身性免疫调节剂用于治疗重度难治性疾病。环孢素、甲氨蝶呤、硫唑嘌呤、霉酚酸酯和干扰素γ已用于重度特应性皮炎的治疗。本综述重点介绍了特应性皮炎治疗的当前和新出现的趋势。
Zotero 插件